The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non–Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results–Medicare
Open accessAbstract
Purpose: There is limited published documentation regarding US community patterns of care for older patients with advanced non–small-cell lung cancer (NSCLC). Using the Surveillance, Epidemiology and End Results (SEER) –Medicare database, we examined community treatment patterns for advanced NSCLC, focusing on chemotherapy. Methods: Patients with locally advanced or metastatic (TNM system stages IIIb and IV) NSCLC diagnosed between January 1, 1994, and December 31, 1999, were stratified based on chemotherapy agents received during the first 3 months following diagnosis. Cox proportional hazards models were used to compare survival, controlling for age, sex, race, noncancer comorbidity, stage at diagnosis, SEER region, and receipt of cancer-related surgery or radiation therapy in the first 3 months following diagnosis. Lifetime medical costs were calculated for each group. Results: 14,875 patients met inclusion criteria: 7,411 (49.8%) stage III and 7,464 (50.2%) stage IV at diagnosis. Thirty-one percent received chemotherapy, 8% received surgery, and 53% received radiation therapy either as initial or adjuvant treatment. Persons ≥ 75 years of age, females, African Americans, and those with more than one comorbidity were significantly less likely to receive chemotherapy (P < .01). Survival was inferior for those who did not receive a platinum-containing agent (P < .01). Lifetime costs were highest for those receiving platinum + taxane combinations, exceeding other regimens by more than $10,000 per patient. Conclusion: Chemotherapy prolongs survival in community settings, but is underutilized for persons with advanced NSCLC. Reasons for lower use in minorities and variation across regions deserve further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Cited by
Owonikoko, T. K., Ragin, C. C., Belani, C. P., Oton, A. B., Gooding, W. E., Taioli, E., & Ramalingam, S. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5435 · Cited by 566
Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
Davidoff, A. J., Tang, M., Seal, B., & Edelman, M. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4052 · Cited by 290
Hardy, D., Liu, C., Xia, R., Cormier, J. N., Chan, W., White, A., Burau, K., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24248 · Cited by 126
Grossi, F., Crinò, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B., Proto, C., Gelibter, A., Cappuzzo, F., Turci, D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.015 · Cited by 111
Metadata
- Authors
- Ramsey, S. D., Howlader, N., Etzioni, R. D., & Donato, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-12-15
- Volume
- 22
- Issue
- 24
- Pages
- 4971-4978
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097124809
- Cited by
- 159
- References
- 1
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non–Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results–Medicare. https://app.cochat.ai/papers/10.1200/jco.2004.05.031
- The paper
- Ramsey, S. D., Howlader, N., Etzioni, R. D., & Donato, B. (2004). Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non–Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results–Medicare. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.05.031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.